Table 1 Clinical features of patients
From: Clinicopathological features and differential diagnosis of gastric metastases
Patient no | Age (years) | Gender | Primary tumor | Surgery | Other treatment | Time span |
|---|---|---|---|---|---|---|
1 | 67 | M | Small cell lung cancer | None | Etoposide + atezolizumab | 0 |
2 | 52 | M | Pancreatic adenocarcinoma | Partial gastrectomy | None | 24 |
3 | 60 | M | Cholangiocarcinoma | None | Tislelizumab | 0 |
4 | 44 | M | Malignant melanoma | Partial gastrectomy | None | 126 |
5 | 54 | F | Malignant melanoma | Partial gastrectomy | Temozolomide + cisplatin | 96 |
6 | 75 | M | Malignant melanoma | None | High dose IL-2 | 0 |
7 | 36 | M | Malignant melanoma | Partial gastrectomy | Serplulimab | 7 |
8 | 57 | F | Colonic adenocarcinoma | Partial gastrectomy | None | 44 |
9 | 58 | F | Breast cancer | Partial gastrectomy | Docetaxel + capecitabine | 72 |
10 | 70 | M | Hepatocellular carcinoma | None | Intra-arterial chemotherapy | 48 |
11 | 52 | M | Hepatocellular carcinoma | Partial gastrectomy | None | 41 |
12 | 65 | M | Hepatocellular carcinoma | Partial gastrectomy | None | 21 |
13 | 59 | M | Small cell lung cancer | None | Etoposide + cisplatin + serplulimab | 0 |
14 | 61 | M | Small cell lung cancer | None | Etoposide + cisplatin + serplulimab | 0 |